<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05082337</url>
  </required_header>
  <id_info>
    <org_study_id>PRT-2015-02</org_study_id>
    <nct_id>NCT05082337</nct_id>
  </id_info>
  <brief_title>The SAVVY Guidewire in Transcatheter Aortic Valve Replacement Procedures</brief_title>
  <acronym>SAVVY</acronym>
  <official_title>The SAVVY Guidewire in Transcatheter Aortic Valve Replacement Procedures: A Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut universitaire de cardiologie et de pneumologie de Québec, University Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut de Cardiologie de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut universitaire de cardiologie et de pneumologie de Québec, University Laval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      TAVR patients exhibiting post-procedural residual AR had higher mortality and hospitalization&#xD;
      rates due to heart failure, with the extent of this association increasing proportionally to&#xD;
      the severity of the regurgitation. Optimizing transcatheter valve performance by&#xD;
      intra-procedural hemodynamic evaluation of AR and residual transvalvular gradient remains of&#xD;
      high clinical importance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Continuous technological development and procedural refinements are important to further&#xD;
      reduce TAVR peri-procedural complications, facilitate the minimalist strategy and improve&#xD;
      clinical outcomes following TAVR. Residual aortic regurgitation (AR) has been one of the main&#xD;
      drawbacks of TAVR. TAVR patients exhibiting post-procedural residual AR had higher mortality&#xD;
      and hospitalization rates due to heart failure, with the extent of this association&#xD;
      increasing proportionally to the severity of the regurgitation.&#xD;
&#xD;
      Various actions could be undertaken to minimize AR and its consequences, either&#xD;
      intraprocedural (balloon post-dilation, implantation of a second valve) or during follow-up&#xD;
      (diuretic treatment, closest clinical follow-up or percutaneous leakage closure). Thus, an&#xD;
      accurate diagnosis of the presence and severity of residual AR post-TAVR is key to implement&#xD;
      the proper measures and optimize clinical outcomes.&#xD;
&#xD;
      The use of cardiac imaging remains the gold standard for evaluating AR post-TAVR, limitations&#xD;
      of contrast amount along with the subjectivity of AR evaluation by aortic angiography, and&#xD;
      the challenges of echocardiography at the time of the TAVR procedure represent a significant&#xD;
      drawback. Thus, alternative tools for evaluating the presence and severity of AR would be&#xD;
      very helpful in this setting.&#xD;
&#xD;
      Current data supports the implementation of hemodynamic measurements during TAVR procedures&#xD;
      in order to improve the clinical decision-making process following valve implantation.&#xD;
      However, these actions entail an inherent risk associated with the exchange of&#xD;
      catheter-wires. The use of a support guidewire with pressure measurement capabilities would&#xD;
      facilitate the hemodynamic evaluation of transcatheter valve performance in a safer and more&#xD;
      rapid manner.&#xD;
&#xD;
      The new SAVVY guidewire, with both dedicated pacing properties and allowing a continuous&#xD;
      hemodynamic pressure monitoring during the procedure, is a unique system in the field and may&#xD;
      represent an important step forward in the process of optimizing the TAVR procedure while&#xD;
      facilitating procedural steps.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patient with severe symptomatic aortic stenosis with a clinical indication for TAVR according to the Heart Team criteria will be treated with an approved aortic valve (balloon-expandable or self-expandable aortic valve) and the SAVVY guidewire will be used for the rapid pacing runs and ventricular pressure measurements.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of Major complications</measure>
    <time_frame>Periprocedural</time_frame>
    <description>Presence of major complications related to the SAVVY guidewire including (i) guidewire kink hindering or preventing the advancement of the transcatheter valve system</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of Major vascular complications</measure>
    <time_frame>Periprocedural</time_frame>
    <description>Major vascular complications related to the SAVVY guidewire are defined as stroke, bleeding or left ventricular perforation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of transcatheter valve malpositioning</measure>
    <time_frame>Periprocedural</time_frame>
    <description>Pacing capture failure translating into valve malpositioning. Valve malpositiong will be evaluated by a landing site to low or too high, leading to hemodynamically unfavorable results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of valve embolization</measure>
    <time_frame>Periprocedural</time_frame>
    <description>Pacing capture failure translating into valve embolization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of effective rapid pacing run</measure>
    <time_frame>Periprocedural</time_frame>
    <description>Effective rapid pacing will be defined as an adequate ventricular pacing capture for a minimum of 10 seconds, with no capture loss, and leading to a reduction of aortic pressure of at least 50%, with/or a systolic pressure value &lt;60 mmHg. Efficacy will be assessed by the physician.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of accurate ventricular pressure</measure>
    <time_frame>Periprocedural</time_frame>
    <description>Accurate ventricular pressure will be defines as a pressure wire measurements similar (differences &lt;5 mmHg) to those obtained simultaneously with a pigtail catheter in the same cavity or vascular segment (differences &lt;5 mmHg in SBP, differences &lt;5 mmHg in LVEDP).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Aortic Valve Disease</condition>
  <condition>Transcatheter Aortic Valve Replacement</condition>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Hemodynamic Measurement</condition>
  <arm_group>
    <arm_group_label>Guidewire</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The SAVVY guidewire will be used in all TAVR procedures of patients included in the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SAVVY guidewire</intervention_name>
    <description>The SAVVY guidewire will be used for rapid pacing runs, valve delivery and for left ventricular pressure measurements pre- and post-THV deployment</description>
    <arm_group_label>Guidewire</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with severe symptomatic AS undergoing a TAVR procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Failure to provide signed informed consent.&#xD;
&#xD;
          -  Extremely calcified aortic valve (Agatston score &gt;3000 AU)&#xD;
&#xD;
          -  Extremely horizontal aorta.&#xD;
&#xD;
          -  Severe septal hypertrophy (interventricular septum &gt;15 mm as measured by TTE).&#xD;
&#xD;
          -  Extreme tortuosity at the level of the iliofemoral arteries, thoracic or abdominal&#xD;
             aorta.&#xD;
&#xD;
          -  Prohibitive surgical risk precluding (according to the Heart Team) conversion to open&#xD;
             heart surgery in case of a life threatening complication.&#xD;
&#xD;
          -  Young patients (&lt;18 Years) and pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Josep Rodés-Cabau, MD</last_name>
    <phone>418-656-8711</phone>
    <email>josep.rodes@criucpq.ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilie Pelletier Beaumont, MSc</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>3929</phone_ext>
    <email>emilie.pelletier-beaumont@criucpq.ulaval.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICM</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Robichaud</last_name>
      <email>Sophie.Robichaud@icm-mhi.org</email>
    </contact>
    <investigator>
      <last_name>Reda Ibrahim, Md</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUCPQ</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep Rodes-Cabau, MD</last_name>
      <phone>418-656-8711</phone>
      <email>josep.rodes@criucpq.ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Emilie Pelletier Beaumont, MSc</last_name>
      <phone>418-656-8711</phone>
      <email>emilie.pelletier-beaumont@criucpq.ulaval.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Josep Rodes-Cabau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O'Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017 Jun 20;135(25):e1159-e1195. doi: 10.1161/CIR.0000000000000503. Epub 2017 Mar 15. Review.</citation>
    <PMID>28298458</PMID>
  </reference>
  <reference>
    <citation>Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O'Hair D, Bajwa T, Heiser JC, Merhi W, Kleiman NS, Askew J, Sorajja P, Rovin J, Chetcuti SJ, Adams DH, Teirstein PS, Zorn GL 3rd, Forrest JK, Tchétché D, Resar J, Walton A, Piazza N, Ramlawi B, Robinson N, Petrossian G, Gleason TG, Oh JK, Boulware MJ, Qiao H, Mugglin AS, Reardon MJ; Evolut Low Risk Trial Investigators. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med. 2019 May 2;380(18):1706-1715. doi: 10.1056/NEJMoa1816885. Epub 2019 Mar 16.</citation>
    <PMID>30883053</PMID>
  </reference>
  <reference>
    <citation>Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarot P, Leipsic J, Hahn RT, Blanke P, Williams MR, McCabe JM, Brown DL, Babaliaros V, Goldman S, Szeto WY, Genereux P, Pershad A, Pocock SJ, Alu MC, Webb JG, Smith CR; PARTNER 3 Investigators. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019 May 2;380(18):1695-1705. doi: 10.1056/NEJMoa1814052. Epub 2019 Mar 16.</citation>
    <PMID>30883058</PMID>
  </reference>
  <reference>
    <citation>Généreux P, Head SJ, Hahn R, Daneault B, Kodali S, Williams MR, van Mieghem NM, Alu MC, Serruys PW, Kappetein AP, Leon MB. Paravalvular leak after transcatheter aortic valve replacement: the new Achilles' heel? A comprehensive review of the literature. J Am Coll Cardiol. 2013 Mar 19;61(11):1125-36. doi: 10.1016/j.jacc.2012.08.1039. Epub 2013 Jan 30. Review.</citation>
    <PMID>23375925</PMID>
  </reference>
  <reference>
    <citation>Athappan G, Patvardhan E, Tuzcu EM, Svensson LG, Lemos PA, Fraccaro C, Tarantini G, Sinning JM, Nickenig G, Capodanno D, Tamburino C, Latib A, Colombo A, Kapadia SR. Incidence, predictors, and outcomes of aortic regurgitation after transcatheter aortic valve replacement: meta-analysis and systematic review of literature. J Am Coll Cardiol. 2013 Apr 16;61(15):1585-95. doi: 10.1016/j.jacc.2013.01.047.</citation>
    <PMID>23500308</PMID>
  </reference>
  <reference>
    <citation>Nishimura RA, Carabello BA. Hemodynamics in the cardiac catheterization laboratory of the 21st century. Circulation. 2012 May 1;125(17):2138-50. doi: 10.1161/CIRCULATIONAHA.111.060319. Review.</citation>
    <PMID>22547754</PMID>
  </reference>
  <reference>
    <citation>Pibarot P, Hahn RT, Weissman NJ, Monaghan MJ. Assessment of paravalvular regurgitation following TAVR: a proposal of unifying grading scheme. JACC Cardiovasc Imaging. 2015 Mar;8(3):340-360. doi: 10.1016/j.jcmg.2015.01.008. Review.</citation>
    <PMID>25772838</PMID>
  </reference>
  <reference>
    <citation>Liao YB, Deng XX, Meng Y, Zhao ZG, Xiong TY, Meng XJ, Zuo ZL, Li YJ, Cao JY, Xu YN, Chen M, Feng Y. Predictors and outcome of acute kidney injury after transcatheter aortic valve implantation: a systematic review and meta-analysis. EuroIntervention. 2017 Apr 20;12(17):2067-2074. doi: 10.4244/EIJ-D-15-00254. Review.</citation>
    <PMID>27890858</PMID>
  </reference>
  <reference>
    <citation>Kamioka N, Wells J, Keegan P, Lerakis S, Binongo J, Corrigan F, Condado J, Patel A, Forcillo J, Ogburn L, Dong A, Caughron H, Simone A, Leshnower B, Devireddy C, Mavromatis K, Guyton R, Stewart J, Thourani V, Block PC, Babaliaros V. Predictors and Clinical Outcomes of Next-Day Discharge After Minimalist Transfemoral Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2018 Jan 22;11(2):107-115. doi: 10.1016/j.jcin.2017.10.021.</citation>
    <PMID>29348004</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut universitaire de cardiologie et de pneumologie de Québec, University Laval</investigator_affiliation>
    <investigator_full_name>Josep Rodes-Cabau</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Aortic Valve Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

